Amylyx Pharmaceuticals, Inc. (AMLX) Total liabilities 2021–2025
Amylyx Pharmaceuticals, Inc. (AMLX) total liabilities at each fiscal year-end, per SEC filings.
$27.4MFY2025 · since FY2021: $17.4M → $27.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $27.4M | -5.1% |
| FY2024 | $28.9M | -65.6% |
| FY2023 | $84.0M | +65.2% |
| FY2022 | $50.8M | +191.7% |
| FY2021 | $17.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More AMLX financial trends
AMLX RevenueAMLX Net incomeAMLX Net marginAMLX Gross profitAMLX Gross marginAMLX Operating incomeAMLX Operating marginAMLX Operating cash flowAMLX Free cash flowAMLX Capital expendituresAMLX Return on equityAMLX Stock buybacksAMLX Dividends paidAMLX Total assetsAMLX Shareholders’ equityAMLX overview →